Aroa Biosurgery Ltd · ASX:ARX
Aroa Biosurgery — Bell Potter Healthcare Conference 2021
12 slides from Aroa Biosurgery's conference presentation, Nov 9, 2021
Slide 1: Aroa Biosurgery (ARX) Bell Potter Healthcare Conference Nov'21
AROA BIOSURGERY (ARX) BELL POTTER HEALTHCARE CONFERENCE NOV’21 Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 9 November 2021 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). Information in this Presentation The information in this Presentation is of a general
Slide 3: AROA at a Glance
|3 AROA at a Glance Well established high-growth soft tissue regeneration company NZ$34-37m1 Gross Margin 4.5 million+ Forecasted FY22 product sales Forecasted FY22 73-75% Procedures with c.f. FY21 68% AROA’s products 58-71% higher than FY21 6 patented Regulatory AROA ECM™ platform product families
Slide 4: Unlocking Regenerative Healing for Everybody
|4 Unlocking Regenerative Healing for Everybody AROA ECM™ technology offers leading regenerative performance at a significantly lower cost than other biologics enabling more patients to have access to the benefits of regenerative healing Price Biologics ‘Regenerative but weak’ AROA Synthetics Produc
Slide 5: AROA ECM - An Ideal Foundation for Regenerative Healing
|5 AROA ECM - An Ideal Foundation for Regenerative Healing Unique Extracellular Matrix (ECM) platform technology derived from ovine forestomach Laminin Collagen IV Elastin Vascular channels Collagen I & III GAG’s, hyaluronic acid, heparin sulphate Fibronectin Source AROA ECM Technology (Structural a
Slide 6: Substantial Growth Opportunities > $2.5B TAM
Substantial Growth Opportunities > $2.5B1 TAM Wound Care Soft Tissue Reconstruction Total Addressable Market Total Addressable Market > $1.4B2 USD > $1.3B3 USD e.g. Diabetic Foot Ulcers, e.g. Trauma, tumour removal, e.g. Hernia repair, abdominal Venous Ulcers, Pressure Ulcers, general surgery, infla
Slide 7: AROA ECM Evidence To Date
|7 AROA ECM Evidence To Date 78 PRESENTATIONS/ 18 PRESENTATIONS/ 27 PRESENTATIONS/ PUBLICATIONS PUBLICATIONS PUBLICATIONS • Advanced ECM technology for • Surgical matrix for dermal and soft • Reinforced bioscaffold for acute and chronic wound healing tissue reconstruction abdominal wall repair • Com
Slide 8: Myriad Matrix - Key Learnings
|8 Myriad Matrix - Key Learnings • Suitable for a wide range of reconstructive procedures requiring implant or dermal regeneration • Especially suited to inflammatory soft tissue disorders (e.g. anal fistula, pilonidal sinus, complex chronic wounds, surgical dehiscence, NSTI)1,2,3,4 • Low rates of s
Slide 9: Reinforced Biologic – OviTex/Myriad Ultra
|9 Reinforced Biologic – OviTex/Myriad Ultra™ • Thoughtfully engineered reinforced biologic for abdominal wall repair • Low hernia recurrence reported1,2,3,4 • Low rate of complications, infections reported1,2,3,4 • Moderate-to-complex ventral hernia patients1,2,3,4 • Compatible with minimal invasiv
Slide 10: Catalysts
| 10 Catalysts Post-COVID AROA Direct Sales TELA Bio® Product Momentum Synergies Vaccinations expected to Fully dedicated improve throughout FY22 field sales team. Myriad expected Clinical outcomes & cost Complementary products for to drive growth. H1’22 39% savings driving increasing every phase of
Slide 11: Q&A
? Q&A Unlocking regenerative healing for everybody
Slide 12: Contacts
CONTACTS Simon Hinsley Matt Wright Investor Relations Media m +61 401 809 653 m +61 451 896 420 shinsley@aroabio.com matt@nwrcommunications.com.au Visit our website www.aroabio.com and find us on LinkedIn at www.linkedin.com/company/aroa-biosurgery-limited/ 64 Richard Pearse Drive, PO Box 107111, Au
Aroa Biosurgery — Bell Potter Healthcare Conference 2021 on 6ix